NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer.
The last earnings update was 111 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
NewLink Genetics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
NewLink Genetics's earnings available for a low price, and how does
this compare to other companies in the same industry?
NewLink Genetics is not considered high growth as it is expected to be loss making for the next 1-3 years.
NewLink Genetics's revenue is expected to grow by 12.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
NewLink Genetics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
NewLink Genetics's finances.
The net worth of a company is the difference between its assets and liabilities.
NewLink Genetics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
NewLink Genetics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
NewLink Genetics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 1015.6x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Charles J. Link, Jr., M.D. Co-founded NewLink Genetics Corporation in 1999. Dr. Link has been Chief Executive Officer and Chief Scientific Officer of NewLink Genetics Corporation since 2003 and 1999 respectively. Dr. Link has been Chairman and Director of NewLink Genetics Corporation since 1999. Dr. Link serves as a Medical Director of the Bone Marrow Transplantation and Gene Therapy Unit of the Iowa Methodist Medical Center in Des Moines, Iowa and Director of the Gene Therapy Program, Human Gene Therapy Research Institute, also of Des Moines. He serves as a Member of Scientific Advisory Board of OptiMEMS, Inc. He has authored over forty publications. Dr. Link received M.D. with Honours from the Stanford University School of Medicine in Palo Alto, California and B A from the Stanford University.
Charles's compensation has been consistent with company performance over the past year.
Charles's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the NewLink Genetics management team is about average.
Chief Commercial Officer
Chief Medical Officer
CFO & Principal Accounting Officer
Director of Investor Relations
Vice President of Quality & Compliance
Senior VP of Drug Discovery & Intellectual Property Officer
Chief Scientific Officer & COO of Infectious Disease Division
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the NewLink Genetics board of directors is about average.
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia. The company is also developing NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a clinical stage indoleamine-2, 3-dioxygenase pathway inhibitor. In addition, it is developing tergenpumatucel-L and dorgenmeltucel-L that are in Phase II clinical trials for treating patients with advanced lung cancer and melanoma; and CRLX101 and CRLX301, which are in early clinical development to treat patients with advanced solid malignancies. The company has strategic collaboration agreement with AstraZeneca to evaluate the combination of indoximod and durvalumab, an anti-PD-L1 monoclonal antibody for treating patients with metastatic pancreatic cancer; Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe and Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.